Center-Authored Papers

Filters: Author is Figg, William D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM et al..  2015.  Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial.. PloS one. 10(5):e0126672. Abstract
F
Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JKV, Tangen CM, Leach RJ et al..  2014.  Androgen Receptor CAG Repeat Length and TMPRSS2:ETS Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial.. Urology. Abstract
Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL et al..  2010.  Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.. Journal of the National Cancer Institute. 102(22):1698-705. Abstract
G
Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia SM, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML et al..  2010.  Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.. Cancer prevention research (Philadelphia, Pa.). 3(12):1523-33. Abstract
H
Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JKV et al..  2015.  Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.. Urology. 85(3):616-20. Abstract
K
Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK et al..  2012.  Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.  2010.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 70(6):584-90. Abstract
N
Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia SM et al..  2013.  Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.. Cancer prevention research (Philadelphia, Pa.). 6(2):91-9. Abstract
P
Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM, Kristal AR.  2009.  Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(11):2807-13. Abstract
Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia SM et al..  2014.  Statin Drug Use Is Not Associated with Prostate Cancer Risk in Men who are Regularly Screened.. The Journal of urology. Abstract
Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW et al..  2010.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.. The Journal of urology. 184(6):2297-302. Abstract
Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM et al..  2016.  Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.. Cancer. 122(15):2332-2340. Abstract
S
Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ et al..  2016.  Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.. Cancer causes & control : CCC. 27(2):175-182. Abstract
Y
Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JKV, Tang L et al..  2011.  Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.. Cancer causes & control : CCC. 22(8):1121-31. Abstract